Truvestments Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Truvestments Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8K	Buy	440 +192	+77%	+$5.67K	﹤0.01%	738
2026 Q1	$6.14K	Hold	248	–	–	﹤0.01%	851
2025 Q4	$5.79K	Hold	248	–	–	﹤0.01%	783
2025 Q3	$4.89K	Hold	248	–	–	﹤0.01%	826
2025 Q2	$5.38K	Hold	248	–	–	﹤0.01%	726
2025 Q1	$6.01K	Hold	248	–	–	﹤0.01%	736
2024 Q4	$5.18K	Hold	248	–	–	﹤0.01%	696
2024 Q3	$4.93K	Buy	+248	New	+$4.6K	﹤0.01%	689
2024 Q2	–	Sell	-391	Closed	-$6.23K	–	322
2024 Q1	$6.23K	Hold	391	–	–	﹤0.01%	536
2023 Q4	$6.57K	Hold	391	–	–	﹤0.01%	561
2023 Q3	$4.57K	Hold	391	–	–	﹤0.01%	520
2023 Q2	$5.25K	Hold	391	–	–	﹤0.01%	519
2023 Q1	$6.48K	Buy	+391	New	+$6.45K	﹤0.01%	478

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Truvestments Capital's CPRX Position: Q2 2026 in Review

Truvestments Capital increased its Catalyst Pharmaceutical (CPRX) stake by 77% in Q2 2026, buying an estimated $5.67K and bringing the position to 440 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #738.

Truvestments Capital first reported a position in CPRX in Q1 2023 and has held it in 13 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Truvestments Capital held 440 shares of Catalyst Pharmaceutical worth $13.8K as of Q2 2026.
Truvestments Capital bought 192 Catalyst Pharmaceutical shares in Q2 2026, an estimated $5.67K.
Catalyst Pharmaceutical made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #738 holding.
Truvestments Capital first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 13 quarters since.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.